AGC
INFI

Alden Global Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Alden Global Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-75,000
Closed -$589K – 31
2015
Q4 		$589K Buy
+75,000
New +$646K 0.3% 25

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Alden Global Capital's INFI Position: Q1 2016 in Review

Alden Global Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2016, closing a stake of 75,000 shares — an estimated $589K sold.

Alden Global Capital first reported a position in INFI in Q4 2015 and held it in 1 quarter. The position peaked at $589K in Q4 2015. 117 funds tracked by Wall St. Rank hold INFI as of Q1 2016.

  • Alden Global Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Alden Global Capital sold 75,000 Infinity Pharmaceuticals, Inc. shares in Q1 2016, an estimated $589K.
  • Alden Global Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Alden Global Capital's Infinity Pharmaceuticals, Inc. position peaked at $589K in Q4 2015.
  • 117 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2016.

Based on Alden Global Capital's 13F filing for Q1 2016, filed 13 May 2016.